0001193125-21-086728.txt : 20210319 0001193125-21-086728.hdr.sgml : 20210319 20210319071556 ACCESSION NUMBER: 0001193125-21-086728 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210319 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210319 DATE AS OF CHANGE: 20210319 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZIMMER BIOMET HOLDINGS, INC. CENTRAL INDEX KEY: 0001136869 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 134151777 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16407 FILM NUMBER: 21756497 BUSINESS ADDRESS: STREET 1: 345 EAST MAIN STREET CITY: WARSAW STATE: IN ZIP: 46580 BUSINESS PHONE: 5742676131 MAIL ADDRESS: STREET 1: 345 EAST MAIN STREET CITY: WARSAW STATE: IN ZIP: 46580 FORMER COMPANY: FORMER CONFORMED NAME: ZIMMER HOLDINGS INC DATE OF NAME CHANGE: 20010315 8-K 1 d154922d8k.htm 8-K 8-K
false 0001136869 0001136869 2021-03-19 2021-03-19 0001136869 us-gaap:CommonStockMember 2021-03-19 2021-03-19 0001136869 zbh:OnePointFourOneFourPercentageNotesDueTwoThousandTwentyTwoMember 2021-03-19 2021-03-19 0001136869 zbh:TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember 2021-03-19 2021-03-19 0001136869 zbh:OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember 2021-03-19 2021-03-19

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 19, 2021

 

 

ZIMMER BIOMET HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-16407   13-4151777
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

345 East Main Street

Warsaw, Indiana 46580

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (574) 267-6131

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.01 par value   ZBH   New York Stock Exchange
1.414% Notes due 2022   ZBH 22A   New York Stock Exchange

2.425% Notes due 2026

1.164% Notes due 2027

  

ZBH 26

ZBH 27

  

New York Stock Exchange

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

 

 

 

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 19, 2021, Zimmer Biomet Holdings, Inc. (the “Company”) announced that Ivan Tornos has been appointed to the newly-created position of Chief Operating Officer of the Company.

Mr. Tornos, age 45, joined the Company in November 2018 as Group President, Orthopedics, and in December 2019 was appointed Group President, Global Businesses and the Americas. Prior to joining the Company, Mr. Tornos served as Worldwide President of the Global Urology, Medical and Critical Care Divisions of Becton, Dickinson and Company (“BD”) (and previously, C. R. Bard, Inc. (“Bard”)) from June 2017 until October 2018. From June 2017 until BD’s acquisition of Bard in December 2017, Mr. Tornos also continued to serve as President, Europe, Middle East and Africa (“EMEA”) of Bard, a position to which he was appointed in September 2013. Mr. Tornos joined Bard in August 2011 and, prior to his appointment as President, EMEA, served as Vice President and General Manager with leadership responsibility for Bard’s business in Southern Europe, Central Europe and the Emerging Markets Region of the Middle East and Africa. Before joining Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical and Medical/Imaging Segments of Covidien International from April 2009 to August 2011. Before that, he served as International Vice President, Business Development and Strategy with Baxter International Inc. from July 2008 to April 2009 and, prior to that, Mr. Tornos spent 11 years with Johnson & Johnson in positions of increasing responsibility.

No changes have been made to the existing compensatory arrangements between the Company and Mr. Tornos in connection with his appointment as Chief Operating Officer. Further, there are no arrangements or understandings between Mr. Tornos and any other persons pursuant to which he was selected as the Chief Operating Officer of the Company. He has no family relationships with any of the Company’s directors or executive officers, and he is not a party to, and he does not have any direct or indirect material interest in, any transaction requiring disclosure under Item 404(a) of Regulation S-K.

The Company also announced on March 19, 2021 that Didier Deltort, President, Europe, Middle East and Africa, will be departing the Company for another professional appointment in the coming months following a transition period.

 

Item 7.01

Regulation FD Disclosure.

A copy of the Company’s press release related to the matters discussed in this Form 8-K is attached hereto as Exhibit 99.1. The information contained in this Item 7.01 and Exhibit 99.1 hereto is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01

Financial Statements and Exhibits.

(d)    Exhibits

 

Exhibit No.

   

Description

99.1    Press Release issued by Zimmer Biomet Holdings, Inc., dated March 19, 2021
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 19, 2021

 

ZIMMER BIOMET HOLDINGS, INC.
By:  

/s/ Chad F. Phipps

Name:   Chad F. Phipps
Title:   Senior Vice President, General Counsel and Secretary
 EX-99.1 2 d154922dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

345 E. Main St.

Warsaw, IN 46580

www.zimmerbiomet.com

 

 

Contacts:

Media

Meredith Weissman

(703) 346-3127

meredith.weissman@zimmerbiomet.com

 

Investors   

Ezgi Yagci

    Keri Mattox

(617) 549-2443

    (203) 399-0856

ezgi.yagci@zimmerbiomet.com

    keri.mattox@zimmerbiomet.com

Zimmer Biomet Expands Role for Ivan Tornos, Appointing Him to New Chief Operating Officer Post

Tornos Continues to Lead Global Businesses and Americas; Will Now Also Oversee Europe, Middle East and Africa (EMEA) Region

Company Also Announces Planned Departure of EMEA President Didier Deltort

for New Professional Appointment

(WARSAW, IN) March 19, 2021—Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that Ivan Tornos has been appointed to the newly-created position of Chief Operating Officer. Mr. Tornos joined Zimmer Biomet in November 2018 as Group President, Orthopedics and a year later was named Group President, Global Businesses and the Americas. In this new role, he will continue to report directly to Bryan Hanson, President and CEO, and will be responsible for overseeing all global businesses at Zimmer Biomet, as well as leading the global operations, clinical and medical education and global R&D and New Product Development functions. In addition to his continued leadership of the Americas region, Mr. Tornos will now have oversight of the Europe, Middle East and Africa (EMEA) region, with the President of EMEA reporting directly to him.

 

1

“Since joining Zimmer Biomet, Ivan has made tremendous contributions toward the strategic evolution of our business, delivering consistent results across the board,” said Mr. Hanson. “As we continue to transform the Company, having Ivan at the helm in this newly-created and expanded role to drive forward, align and execute on our operations helps ensure we continue to deliver for our customers, patients and shareholders.”

Prior to joining Zimmer Biomet, Mr. Tornos served as Worldwide President of the Global Urology, Medical and Critical Care Division of Becton, Dickinson and Company. Earlier, he was with C.R. Bard in positions of increasing responsibility, most recently serving as President, Europe, Middle East and Africa Regions. Before joining C.R. Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical and Medical/Imaging segments of Covidien International. He also served as International Vice President, Business Development and Strategy with Baxter International Inc., and prior to that he spent over a decade in leadership assignments around the globe with Johnson & Johnson.

Mr. Tornos is an alumnus of the Harvard Business School, having graduated from the Advanced Management Program and he also completed leadership and management programs at the Cox School of Business of Southern Methodist University. He finalized post-MBA work at the Wharton School of the University of Pennsylvania (CPD Marketing/Finance), holds an MBA from the University of Miami School of Business and a BBA in Finance and International Marketing and Management from the University of Georgia Terry College of Business.

The Company also announced today that Didier Deltort, who has served as the President of EMEA since August 2018, will be departing Zimmer Biomet for another professional appointment. A search is underway for a new President of the EMEA region. In the near-term, Mr. Deltort will continue to oversee marketing, sales and distribution of products, services and solutions in the EMEA region, partnering closely with Mr. Tornos.

“We wish Didier continued success in his next career endeavor,” said Mr. Hanson. “On behalf of the Zimmer Biomet team, I want to thank him for his strong and collaborative partnership over the last three years and for his commitment to ensuring a smooth and successful transition of his responsibilities.”

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and

 

2

market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this news release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this news release.

ZBH-Corp

 

3

EX-101.SCH 3 zbh-20210319.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 zbh-20210319_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 zbh-20210319_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member] One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member] Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member] Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member] One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member] One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member] EX-101.PRE 6 zbh-20210319_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g154922g0319021031101.jpg GRAPHIC begin 644 g154922g0319021031101.jpg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end XML 8 d154922d8k_htm.xml IDEA: XBRL DOCUMENT 0001136869 2021-03-19 2021-03-19 0001136869 us-gaap:CommonStockMember 2021-03-19 2021-03-19 0001136869 zbh:OnePointFourOneFourPercentageNotesDueTwoThousandTwentyTwoMember 2021-03-19 2021-03-19 0001136869 zbh:TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember 2021-03-19 2021-03-19 0001136869 zbh:OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember 2021-03-19 2021-03-19 false 0001136869 8-K 2021-03-19 ZIMMER BIOMET HOLDINGS, INC. DE 001-16407 13-4151777 345 East Main Street Warsaw IN 46580 (574) 267-6131 false false false false Common Stock, $0.01 par value ZBH NYSE 1.414% Notes due 2022 ZBH 22A NYSE 2.425% Notes due 2026 1.164% Notes due 2027 ZBH 26 ZBH 27 NYSE NYSE false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document and Entity Information
Mar. 19, 2021
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001136869
Document Type 8-K
Document Period End Date Mar. 19, 2021
Entity Registrant Name ZIMMER BIOMET HOLDINGS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-16407
Entity Tax Identification Number 13-4151777
Entity Address, Address Line One 345 East Main Street
Entity Address, City or Town Warsaw
Entity Address, State or Province IN
Entity Address, Postal Zip Code 46580
City Area Code (574)
Local Phone Number 267-6131
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common Stock, $0.01 par value
Trading Symbol ZBH
Security Exchange Name NYSE
One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 1.414% Notes due 2022
Trading Symbol ZBH 22A
Security Exchange Name NYSE
Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 2.425% Notes due 2026
Trading Symbol ZBH 26
Security Exchange Name NYSE
One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 1.164% Notes due 2027
Trading Symbol ZBH 27
Security Exchange Name NYSE
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /LYQLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #[.7-2.'+>Q>\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O:9EBJ'+BV-/"H(#Q;>0W+9@DX;DI-VW-ZU;A^@'\#%W__SN M=W"M#D+W$9]C'S"2Q70SNLXGH<.:'8F" $CZB$ZE,B=\;N[[Z!3E9SQ 4/I# M'1#JJKH%AZ2,(@43L @+DWI\65>M[ ^ MD?(:\Z]D!9T"KMEE\FOSL-EMF:RKFA=54_#[774G^$JLZO?)]8??5=CUQN[M M/S:^",H6?MV%_ )02P,$% @ ^SES4IE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #[.7-2.\#4>5(% !E&0 & 'AL+W=O9YO4[*XZQU>ES>FZC38UGH),[$ M1)&\2%.NGLY%(MQ 7(DF, M$G!\WXJVJC9-Q=WK9_6KLO/0F7N>BPN9W,617IZT!BT2B3DO$GTKUQ_%MD-= MHQ?*)"__DO7FW?Y1BX1%KF6ZK0P$:9QM_O/';2!V*OC>G@IL6X&5W)N&2LI+ MKOGIL9)KHLS;H&8NRJZ6M0$NSLRH3+6"IS'4TZ>7,BP@R)KP+"+#3,?ZB8RR MS6A#U(X[&AHQKW;"K>#Y1I#M$1QSU2;TZ( PC]'_5N\ 6P7(*D!6ZODNP+-: M0/+U,U0@(RW2_!^D.;]JSB^;"_8T=P9M165[5PE?U'4?KS_G22X0CJ#B"%"= M;4\O@$3Q!'H%*GN=1ZO<&O2,$JUMA=5&Q:C1F3RM1QX)7'QQ^ M0B!Z%42O&<1$J%B:K(@()'\M#Z[TG*R_O'OG2-=^Q=9O,FZW8A'G,'( >DO/1S7@X(Q]O/E^.KC],#\CH^J*-8 XJS$$3S%$62K62:C.5 MIAJ"2"YD 3D'J2>C6FY<^'*(T!U5=$=-Z*[B1)#K(KT7J@X$UX"L/Z2]P.LC M/-2S+NDU(9KQ1S**(/7B>1QN@K:?SR%)_<. =FF_CQ+N^#AM0G@614KD^<'S M!2GM\2:K'4J'I!]TR9#GFHQA=8?L4+#(8*S6TBG[(=8+4Y**S.2Z?L7!Y>ZX MROD:([/N3W'[?DFVF1* -E'R(<["^C#BFJ-K#,TN"+31BE"A362N867X$J_V M3E6'8M#K#CR,S:X*%/?U<@#/8%>X'P47^+W;#_[ 4.S:0'%+_RQ#B,ID*3/, M.QPBK-<_[%$?6Q"H71$H;N5W*M9:9!":-"VRK6_DM52XD&MO0:W[4]REIS*) MPUC'V0+FMH95E">U/+B*D\?Z/<7->J)$&1X!,VRSO8!=F%#D9C[?,WZXGHN, M6>-GN$O_CVR4YP60N0 =LDY Z_NLD>\/4Z$69CP_@()>&N85SVJWBPY!)]K. MSAWW91.W:_Q:& 6?-EN%5.15@HTPIE]V06ZZ36 MY!PBN_$X(+]Z;8^2%5?D@2<%&G'KPPRWT9GBD4F"Z5-Z+VNGM$/@R_E'#,2Z M,,,-M(K7\#%<\FPA]FZ#'4+7?T^Q'26S+LQP\X0M$"R9L3G8R4*9'='F LX0 M(602-XA2BYQ<%H+,UI+,EK+(S:EXMH;G3^6])DEL39@-WB2)KN^2. > MAF?=U_]9]W4(E F,LE@#]E_+@!U"KORU!NPW-6!S99+QQ_QW*AY@$]TD@:T# M^V_BP+YU8/\U'-@A0MNT]]*!L6\(@77@X&<=V"%0)C#*8@TX>"T#=@CM2^#. MSD=S\P/$F)L-=$X2,0<=K]V'N:HVW_0W!2U7Y7?T>ZFU3,O+I>!P"C OP/.Y MA!'9%LRG^>J7E=-_ 5!+ P04 " #[.7-2@ZFE ]0! R!@ #0 'AL M+W-T>6QE1'9!20(J+ @J"SL/OG:22M+0-SN5 M,=FOMSN=V[@,J ^B+Y,ZIZI/G;Y.UN,DX:D#0#(JJ?N<=HCV+6-]U8'B_2MC M0?M,8YSBZ*%K66\=\+H/@Y1DZ>ETSQ07FA:9'M2#PIY49M"8TQ-E1=88O3.O M:21\*5= +ESF] .7HG1BKN5*R"G2:2 J(XTCZ*U 3I/ ],\QG4047"XZ2FCC M LEBA_A;+N4_)5;4>RBDW RF-!)%9CDB./W@P5P\DR]29(G/D_4.6\>G)+VC M^X#YXYN4QM7@MC8)7:DBD] $.TZT7?BBL2PD$8WR02UX:S2?/:PCEL#+5B#E M4]C"K\V5]MB0N!_9$LL>)B\/W@9Z-G M_&TP"(\.&C'.>&RV_K?4D]OJW%HYO9.BU0KBW'^Y89'Q=1SIC!//OELX*94G MP%%R 8>B.C+?';=G&'$]36-SVW/Z'WK^N^O<@@;'Y=&T/_K_\BK_CF.VW)[# M%;VZH!M+PD.8TR_A?96[!U(.0J+0"^I$78-^<4^]//+2/^!7^KZ^AH8/$L]; M,J=[_!EJ,:@W6]5C6)>E:H\_A?* MNQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %( MMB6/:(7->=I3W;+T]! M;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B M':5_'FR-9V87YTC' M?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X3[+O,&@ MEXN1:T/9=1,92L88!.R '<(Y_A^[<#K3P&]'@!6^AC(,=D",Y1]XVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F- M:#R!+ ]=R_$)'0.M#,,SQ;;!<.AHQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&' M' E<)S"D&IND53 >"CVN*!.L>@PL(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T' MX:-:"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$ M% @ ^SES4B0>FZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*] M:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8V MP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X! M4$L#!!0 ( /LY-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0 M]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K M'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+* M&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>= M(\G=560C2&2FKW@ALO7L^T%.6X.^DQ>\ K @ $0 @ &O 9&]C4')O<',O8V]R M92YX;6Q02P$"% ,4 " #[.7-2F5R<(Q & "<)P $P M@ '- 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( /LY&PO&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #[.7-2 M99!YDAD! #/ P $P @ '/$@ 6T-O;G1E;G1?5'EP97-= :+GAM;%!+!08 "0 ) #X" 9% ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 5 95 1 false 4 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d154922d8k.htm d154922dex991.htm zbh-20210319.xsd zbh-20210319_def.xml zbh-20210319_lab.xml zbh-20210319_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d154922d8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 5, "dts": { "definitionLink": { "local": [ "zbh-20210319_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "d154922d8k.htm" ] }, "labelLink": { "local": [ "zbh-20210319_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "zbh-20210319_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "zbh-20210319.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 31, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 3, "memberStandard": 1, "nsprefix": "zbh", "nsuri": "http://www.zimmerbiomet.com/20210319", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d154922d8k.htm", "contextRef": "duration_2021-03-19_to_2021-03-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d154922d8k.htm", "contextRef": "duration_2021-03-19_to_2021-03-19", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 4, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "zbh_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.zimmerbiomet.com/20210319", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "zbh_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.zimmerbiomet.com/20210319", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "zbh_OnePointFourOneFourPercentageNotesDueTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member]", "terseLabel": "One Point Four One Four Percentage Notes Due Two Thousand Twenty Two [Member]" } } }, "localname": "OnePointFourOneFourPercentageNotesDueTwoThousandTwentyTwoMember", "nsuri": "http://www.zimmerbiomet.com/20210319", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "zbh_OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member]", "terseLabel": "One Point One Six Four Percentage Notes Due Two Thousand Twenty Seven [Member]" } } }, "localname": "OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember", "nsuri": "http://www.zimmerbiomet.com/20210319", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "zbh_TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member]", "terseLabel": "Two Point Four Two Five Percentage Notes Due Two Thousand Twenty Six [Member]" } } }, "localname": "TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember", "nsuri": "http://www.zimmerbiomet.com/20210319", "presentation": [ "http://www.zimmerbiomet.com//20210319/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-21-086728-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-086728-xbrl.zip M4$L#!!0 ( /LYY+L.!<)$$+3S51-8UO7T[O?TY&C?PW[/KEG4G$1?,@YQ7*.L, 5'@_N M/N3BJ%LXR)%_'?_S'T>]""I"Y4#5/<8_Y'I1%-9+I6%'^D7%W.*=N"]!0:E2 M=FJ%LE/8<7*V>JP*T2AD*FW3I:I3%/*NE)3,:12(((C[:9/!8%#40V$S+Y(E M;%>"2@6HQ21WDW9#GP=?)YH-=G0CIU:KE71I4G6F9CI I5S>*6%QARJ65/^[ MTYNH_3?OP\@=+OHL*KJB#ZTJ3GG'J:6@*#X/$.C<*?UQ\;GM]EB?%GB@(AJX MZ3!Q)!<"52M!:5*1*U&M./L/S,#62!L,%]5UH&X \V5_G-Y\'E>/YM3$WHDSEM' QZN'?B$<^.SXH M_'I4,H_P#=B+$NRAP/X;\_L/N88((A9$A5L0@1QQS=N'7,2&44GW2$K8KF0[ M)80<=80WPL\5%IPV?*G75;4?"_7HRY"JM MT1#]O@CT]PO6[S"Y 4Q;=+$[A,R^>S#>,/2YRR,#!_$X%!MWPP);7SB=W'%2 M968^1Z6YW8\Q/8;CQ^( 5"M7 ;L6'%0SR"8\XY]K!E(:1/2.78J(J;.8W0[$ M;4_$B@;>[0"*1O#A3?,*S+S^S)F_<]4#7 582G$+S^?\GJV VS8?OGFN>N;, MW[EJ!5T%?P%A*PILF]VSX,VSU7.G_AWP56G*ARQEPY 2A"O'$T$+MBI0G]\% M=<23H7ZF?,"]J%<_*.[RX#!3UV?=Z+!/Y1T/"OA<)S2.1/)%\KN>_83=A4EG M&)X6>DR7.L5RF'81B;">>>V(*!)]_:4C)(">?''"(5'"YQ[YJ:S_RQW_\I.S M5SX\*H6+!MI9/E#ER0-ENJU")V1V J0+I"DH_C>K.P?I>Y?VN3^JWP*'*W+) M!N1&]&EPJ,L&!NZ.\+W#.>3Y[;)UVSPC[=N3VV9[,3CE#8'3;C9^NVG=MIIM M00S MY-@ 5YU?W5R0(Q72(%5$/1ZQ GQQ63T0 TE#"*D7I5+.A!NCGLYD=%9/5^AL MT62>XJB$H!R_<\R+<,Q:9!RTT$WS\I;<-*^O;FY?7^=,G+@1@6*GME-=#.?&*(N> M#X)SPT(A([*5O#,*G@]3$4'_+2)2%S-ON[XXQ9KHA6OM/C6-5_58!4%,7OU# MC@^CNH?^*#3O>70T HA8D#N^H-+M ?;R!%O-ZI)W);)^)5*IKH/5%C*.283? ML#NN<&DENH221QN6/UL7%\T;DD]7G\]:EQ_;>=*Z;!27<,GC]$-Y M';C8:@XIZ '$ 4J;3.=.J"(J9"X&&1(J Y0/CDM%Y[Y^X%W/T]V+#M75_@^#16K)P\/\\@T0QET..7RSQ9Y M];*%LUY.0CV$3)H_WF0$N5/]&9= (F^J])[)B+O4M^@U,YY;T_93>40_"E4V2)A^IOZ+X/#)X89!\CGW&91A!NWQ*Z1.P=FKEO<78NQ[ M1MPM';9L=M#5F'HB%IV=0M79=?;W5T'C2TC[P6:$?4M+,(82 CQX2?X"!UYY M7,<81QU)2NC;\ZS(;W_;#+2%BY% M)I>BN#W#>/ /6O!GA%9K\?&6".:)YTFFE/WS&;PLY]%"N5/=)4T*4=H%!5>Q M'4G&HF_/V5T-$0UXO)*W8A \&@V_4ZGH8'KB^<6AZL3 6N"OY#786*YW6:W; M8K<"C]. +ML_M "\:P$=^G_R\"GNQ'%U;_>@O$Z66$L&4A] MPH;,C2-^CR$12#A3VV0+YDUPX@_D=#8FT.,(]9>?#BK._J$"I>>SL"<"1@*M M4/-H&OP8@P0"/AH%W9[GJR0[#9P'J^1IG\T0? MH;*W7]AS=N9D9>9E>%^#A)<"(NP0EQ_10KR^')R#[@ GP^0!I%8E\$J-= S M=8G)&H*91=U$?%3V)AGWG@U88ZY+#\L#="[JU9\?Q7>YXT:/N5]UOA=82PI0 M:.A!=L20=)@O!DA%+$1:+Y=.O4"BQ85TN8]ZA"M0*A$#X#S,=RO>C_V(!DS$ MRA\1!4*INB,]@FT@.H _XQ_9/'0FOQ1#/\!AP2@IZPH?@,1V:+,X^HF*;,UZ M9OJYSL$6<3=WK!@C%LZ/+& 2U'""">&?;1[)M6^A-/C#R!:A# MT(G^#\RS8V1 UP8;LPR[U#8X55IP*HEY&//VQ-IBPME+>ZM4RT73XW;&07L7 M@G4*P;5DJ+?Q"(+>,H%67%YUNX]WKK\C85C*F8"U@IM!6\+QRS3^"@+D%2I; MG>WUBI#I\UV(-B1$+:5B)M]%Z95%:8<5JEON>D7)]KFR*+UT"@$,]]AM-$$4 MDQ"&A?/V'Z$22((JF/KBN.=]4?H[7I1^RC+5"AF2!;.=(T@K)[2<%TAHW>(Y M8+-_S.T1%\\1I$+\PNM+3T7B:V-,4I1>L[K5'O6AWI;:?D?:PVE=TK7?"+Z6Y[\7[E8=DA( M);FG?OS6=J@L0K"54".;&\7NGZ>?OA,<)DR:^(9/V.+Y+%3.N/RH-)+U693K M_Q?RJV'CU']]"/7OFN3U3GL[Q:I3_9GHJL2+&6X$KWPGM1"J5 MD^\$XYO13.M _ ^EP[[1'4N;49'/OKJ@@FM:4RIR[UF[@)SO$,W//\OO%)V] M:5,T9W_L9F*Y-R1&&S!SSY8A;>;>DM!LT'=XNL1HK+Z+R.HJ\.7]DN=*RGK\ MDF]6K#;O(#Y9NM9%B4VNN9CMT:[>,3TP"I14 MYOK498BG+G%CYHIK8I5.(=V>L=H1\.6=)M#A^MA,_QDP7W9W;>ZXN0#E2W:Q M)\T^ZE8-TVAC*[8OBY)6]P%>Q*W@LKL^?06+6GN;-%T27.">U.$+UKB7.7^H17N%WK#%QF9?ONU-*TYY M[JX5HA^!EV:W8\PFH5I@_ V#[!;+E3D)LVQGK[7'Y"%GR2YP!N J(OIG$D#>YGB1/_M3WKI-3??$Z^03X!%Y4 M>=(*W"+90KV*9XDJY4-K&?6;<[@-JCP ;>VBYN_1B+3N@;%NA0R$TN:B SX= M'C= +)IS =@7Z'Y_5'"!I?%C**S!0)3U..N2*S =5%L B[I$N=O1#2(W>7;B M0A8-RLS<\@1DDE1W\^0OH;VX#'#HT5V*>W-]8:7L'*"W!VY%'))KR92^ S%/ MKF34$R$#RXN=!=H//&-NVJI&!M!LC+F9#C[Z CP+E./]BHH ML-LU&&")2$Z!/V'C A )VV-\D*/,[[ 2G M@%8;!F^@ XDO#0I"=\:34QK0]!0E"F]>X^Y74&) ;-W 8FS+,M?I6 MHG>@SX_D2:-(;HKD%+R!A"N31O I:;9-NE+TR;_C '-TN\B"V)V 0GXC.#-6:L02J0VON M>6!J]*%8G.E)%TF6SJEYT3Q)46%A #89BPIT;[8/ $DF&04/V#+PM!-0=XHS MH%J>329V$M_% 9>^(^PY/&HHV$;]-MI1@5.S06 S&>XYC\@J1F&P6DE9VXN M: "(XWWY^N;*%6/A^#]J1 XA'>X#SZX=A43 MOJ?LGP8 H.B^,M#$>!YR?,9H/N:!L[3[DDJ*P?AB$5EALLD>.RN.Y+I'(3IP M61RE$F.EI]3J4PURVUPM:JP'>KP: VSB-WC$&>[&=R OE4D0"?WS-?A/UD6FU :@M3[Q?:#P^33\@2B3AH?/$ M#8I"-$ZRU>:MQ:6PYR'1"((.T%:P#UR?&$ VA)@*(76S_@/-^@\=%@VP6=:R M:):9PAK'$T9!8-T7C;0Y8KO KH(RC"5*51[' ;9!Q1V(24B 9GK7K([&T"U( M89O1@0"?/K*G,R(PF)K>M#NAM%023,*SGN:*QO\3T[X%P&D( /3VS09AT"EJ M'&).MDN5BI=U!:H &];+$.^IXD->5=8Q,#<$D_OZ(Q-EZ7+F^4.BOFDW*Z(:3:KEJ@UM08[&9 MYO)D3+OP:S%)P&R:^6^S#(M&<>PBBKG>I_$-;^P\=WZJ5-WQ\ZTE' MKU:2DA5.WY#DAP\UM0M(W<>7XS%O[0,]M(:2UTZ)-S?\/2K1A4C^ M40CJE*LO2L^&@*_D&E=M=.H2LR_WC)S1B!)]T>@6)LP]=)_1@[>!?DO_F"[! M7],EGOW9@.VL_*4&'!_'Z^A:+'_HQ?17W:S8;GV\/+G][:;9WGCR*_N+'V;W M#*;WQDO"*\5R6.EFHOW5YFT=V#\OKN9S5V3L( MC+ L]#JG@JGTS/]C_- 'KQ$XV)_P0V=]A@VI_8P-VED:$#[\*QD/G@U:Q6(B M9SUD,G7YMV0S<\>GH_H:=IZ_U/4,2_:;/5)9E%2)-'K4(^=%<-HN!-@MPS7AZL3I9:L=?L%#,K*6#694LHG(TST%+ M]S?.N&E'I8[P1O %?'O_^']02P,$% @ ^SES4C>0QUB\#@ #3$ !$ M !D,34T.3(R9&5X.3DQ+FAT;>U;V7+;.!9]5Y7^ >6N[DJJ)-GRDGB+:K3% MUHRWLIVXTV\0"4F(28(#D);57S_G J!$R4O2,W9FNGKRT)8A$+CKN>=>N@^/ MKT]/6H?'_7:O5:T<7@^N3_JM_J_UO;U&\W#=_8KU=;^!'7;.>U]8YZA[?G)^ M^6'MYGAPW5^C+UBU@GU=D61"MPY[@\_LZOK+2?_#VE2&V61_M[$CDS7&(SE. M/JQ%8I39IPXOBFTQUV.9U#.5[F^DV0'SOP]5EJG8+8U4DM6-_%WL-Q>_CW@L MH]G^M8R%86=BRBY5S'%3^V1P=/9A32#.6NN79&C2 SH%BC^EQR-J9.(^J\LDA*GVM][_3':PMAN< M'K&KR^Z'M7%S9WMOLL:E*ZV M*ORG-FQM;>^P?H.=&3VML<%:M;+_;V=UX[0L//[6F MTVGC=QG'0@^EBD76"%1\N/ZIM7KU"T5')!-1GP@*ROVMQL:W3J*KADJ'0A&17)D/VT8?^5;WK-6.CB2QYD9I\]$_$O$Z[6R]NE@P?.QMT9AZ6_QM-4$8N>7E$H11X6EW3OJLVS\YN;IH=P=G M1Q_6-M;L[Q?M7J_X_6;0NS[^L-;.P-8R!\]6Q,N6_] K!-EI KY1)GN+;S[[IYVJ"Y&+CFJ0J64CT5]J 6_1"6(LT&R9TPF=+&^;2S M).6*,MYGA>>>WK?0Z(=I4PI%MAQ\[-&L\$O$1/:;C8T-$2]7YGJQ^(?2I__[ M6+(O?!Q("NP7,"4[.[^Y;%^T_B&T1"'&VOU?UKAOWC7??P=D@CS5-[>WMSQD MOK CWFQ^'V[O[=4W=G?>S87XB_H,"".0$XT9Y<2#0E+4D1?T#RZ\1:XT8ILK M3]RXP%O\H,KS!+?8W'[!5J2H)\#=WZQ4K&/%8OW[E">AP?9(X"3-!G<@(-=* M)\K46#M-E4PRF8S9L8Q9INS1W8D4(W:>"LWM5^>CD0QPY(4RV9PPO29+>Z#5 MH.4D9L0499)C-V0]$3QD1Y$:\HAU<@/Z:PR^@;ZL#1/(@)L#=B.CB)VI*6M' M1K'S.Z&-$*R?:Y6*&CN580C#]#DTL\^-Z#'VIG_:;[]EEV(L%=&UP7]#Y:Z* MX;N9$[R=)"I/ CQS$?$D$2'KB93K+->"J1$C>=F%%I3F2<9Z,I1P6$]$J+[9 MMQ1XR9ZX)#]%&VVXT&H$S\"2\)./N)BD_!%VI8QX<].^O&K?4//WUH9OQY(1 ME_:G7 <3][&Y5V.;:(I_^:FYTSQ8SJ-C%87(!>3,( D:[,W9EZN^C9BKP:_[ M[+?.\=L:XVSL@C%"8.)1=+9Q;H(\4N961"+#-Q/!HVP2<"UJU4JF0C[#(A6V")6(:S>H!P)T64V5D1I&*2'@B>=%IZX93 MTQ_^%2?BV64U(?*9NA/Q$$N;&\U=!@F.M,K317#5V+G.)LB>4 8NV3B;":Y9 M!%DTFW+CKDEX+$+WIP<]N^13"=N0W^).1"JU631"\-B#&PA-QL/0A0),0'8K MK!3ZH#03F5*8E$T-]0GG:@]"Q)H'K .!>"><46BZ4#S_72!:K12G3ZD'IN<6 MSBB0R_F/;%9VX43&?BY$\ZCT>Z=@K(P0NROMX \#P&8A.?& WN S(,(41<9*OEF<)(",$=8LTP+) M$*K<1;R6P]SF!,)HRK5#%I,A Q&+ 1-W*LH]8"(U9/@YU&LRIT29D6((K")(8.#&V M!_DZ7Z,LHVNM9@ 8^FXBHIA N<# $NA3I@G+[O +02.='&H(3Q!&6M>09DA@ZY[J,1W1':IA(#'&)%4F]-1PHPDY!CGX>;H"A4CP.TSCD-A.4M EJ M)+YJ>)N\]M3P0DM(!2&?B)!5-#-"WXFP6D',W"@=A8CM%2PBB_O*] D656,X MY=3CLZT;&MA*OW2A+4C6G32^ZG8 6H1Q/1G<2G*^V^\\VP TZ@B$S!4OJA0$ MA=W&98-U*#KAX**$&SH-<0\G&])I7IED)#.($Q,'!T1"8H DJ62+E"G7YR=P MN5KQP.QH+>I%QR+)W'YS@9ZR'=WS&6QBI9P>B03!%+%3G@"E](/RD8XDMIPH;3@2)" \ <> M+-57#K8[3IQ"'-S'4QLJZL+=^77.8D-T'CQ8.H>- 42=M6]%\'F6R$5/E^I'!MT@J "+PV!V.Q3(BU9 MR68V;$82+H5QPF_/5I"'6?VTTRYFXE.E;PL1;A#'R/*2&+2ZN(M6+D22F%D$ M0T@PH.Y%#\;0MX*XS?I'B '[H%,@I+1&QTW6?F@&'AQU*N&_QW1VG+N#1Q%V M_E"[N!S"\XM=QBU,.W?8\GU'0B&N.+L66L]@[R@28U&^^ >$YO6B'KI8*75' MMENR2;C)QF&DLHVOD85* JQ: M2!^CMSS]K.Y4&5\:R7<-C2=M?3<5V' V,+O_/F M_4&SXYL3LK7S;PWT(_(M%(5_P7[HLM1U#*C7ME8$?IOQ!,@X!)0,D-]QH_N,45^- M32""@M\I_3WD[#R!]R<\&A6><>ZO5KS_,\'ACP&J-ISGBD!R2YV)]2[=#'LK MGV,!K[U[BWH]4 M7(5E4,V]S?>^S/#PGSF,3^\:JQ7IJ^S\+P"24 (+:ZN3#_/'YC<-=D.H084> MK(PG^8@'=AI'(OQ9F];-_S>M_WXL$GTA1&9J/A\CIHY\S#0@V$*"1V-@$@T\ MC)O^H+C6V%!2PR$#(#6@#.VL36 W%M,\CWGI865G>O4A-U0713!)[+/"GFM/ M"P -B&M^C^*A$)G2\VX(IO%;4#J,RA)-J"1(&4 .*[11B\B2.T#0V++VXH'7 M!_X;40)2SY<7>@W@Y(Z'VD4B=ZZE2M2=948-=HY&ME '[>!2.:1F MF*8)8!GS!M?DHY&;"%CFA!)K_VR&R&<-SL;97P'4]IT$_*A E6JVIZ)V1N/I MM!AN&34"0DIC16*E@K*CK$5"A0:$;-.>I71OT+??X1 M% WN<>/ Q02!@)(:22J.;','[LMI!B.6W#.EGMN5,)J3%@Y8?ABYOGBZP3[" M?O9+F="XQ%Y7JU:H[\X\/C[]9U9N@Z+A!9)@NH+W*)K7,#Q9CB^?E;EE.F:] M?"Z=^6STOU0E[7(;C!PL_$PA ]"OHQ.S;.RCF^S43Y2ZI8BZRI BKM'\ =66 MWL/Y011Q#91)X\9%7"(*_-2I'GG9S$(VBG!/-&/![;#!TRW#1Q1/&LE.(>$F M*O,F]$)+)*VH5JY$D&N'B"?X,7:3\DMAAVCMP/+JYM[>C@V9IZ0 ^X_RD+ 6 M1(42#;P>:0.DM>U%K;P76@7HI1XT!$2HWAT8FKR)("LF^H2<]$,K0\NFF!RX M:;V+>I M:;:=(8XQ^? K]A 8$D&1*!?$7[4TMY"-^BE-/IM7F "Y-Q8V%P.I@SR&6/9E MHVVWD)#(W(#G\#:1'%0#4#VDAW^Z&([2O%"2?A )"82:$\U<#G.8V;\< &4* MM$P+UFIPBOU)QK#RN4G DHS4O(C'_0 0DLI56E=11S(2X?Q=@TOL3XTK3_Y+ M<43"].^=YD198VDAE[VYZG?? ITG NH2J5- >C.Q-J" &=J0IYKN6DUQ/X%E M;'EWDU"[T[Y4XI:88O=7_XYF\0[$=I1D4Y_IU4HI$JS5N84]&['VF$?5A[84 M3(MS(?RS.8#XY+< /W1T?)YF(=59?)C92VF@[@)X&3%1]X*(2QK)@-S3Z\C$ M>5$S-8R*G$00Y*D]$.M:(*&%W;^"#F5]J8%WE9 3"7?A1+)1ZUQ&?C;*+<46 M=\(75VM&-(B@XY=NEN1T6@4ITLL;6S@WVK>&L(++-".>@:^:'QS0770,M8PX M@\9\N?9,PXV(GCW&=O)VB'!G:H1OO MT\O(9R[P4.SBY8$1&O,7[J_)WMR$#8C]](SMM\YQO:MT6OZ[TS]CM[3U?+>$ M@GS>^X)%^[]!_ M02P,$% @ ^SES4M),0.]S! I!, ! !Z8F@M M,C R,3 S,3DN>'-DS5=;;]LV%'XOT/_ Z6D#)DMRD 46XA39W P!DC1(W*%O M 24=V\0H4B.I..ZO[R$EV?(EKB_M6K^8XCG?X7W?Q]LWY+[Y/!E?7=\0G$V,*'0?!=#KM9",FM.2E M00NZD\H\(+[?Z/\U_$C^J:S'Y $X4 VD&W9#_XS\63*>Q?8CBJ*P$[5A"JBU M1S)J("8G0=0+4#$BO3@,X^XIN;PE[ZDVH 09LAS:4%G,%!M/#/DU_8TXT$ * M 9S#C%PQ047**">/#>/?R;5(.^22<_)@81II:E#/D'5JJR\ZBW4Z@9R^?4,( MQDOH6*#),N][-A!U'%X2Q3M2C8/,J,#,"@A0R4!+U6I@,V!SCN&E( M.V/Y'*!@\RI6BVWVJ1N&)P'6A\&P0PO"F?AW"\**$RR5]B)KD.F) T2]7B]P MTA5*F5GVH[9^&E3"EK9FZ6:746!=CM9/KLR]"PL@Q%4^RPNI#*DVP(U,W;[E-QQ>(X*RU/7OLVIHB9SM062!/[92 M6MW1YN5TZ_*K[73O)&SLF0%PHYN9'7;,ML;[C1FYUUI^];6C^I[QF,]O4=(4RP[9X/YCI[^VW7 M&*(&L8./#]?;[S;SRTU@Z(L4,I]5) T=JOF_%-E[@>1FU[BG5.Y2XA&& MMZ '5'_:27U.M*&ZB,1%%-H?/HD:"^TA%1FIS)&6O?-@U5KR><'5X%IC&W"U5'='+B=Z,ZZ>;9+6-+!@M8/5,\N=SO6Y^K+K8MQM<&A=? M6\H'^,MB]CV]_"#@7C+[EBD5CNW?/0;7%N08[J0!/2AA.)7#B2PU[I/A%$4S MG+B%/ '5^'^TF2HRU7,]SF1.F?C1H4%V80>?'MG+%V?F1PJIY9753Q\PM02P,$% @ ^SES4DW-LJ0E M!@ J#@ !0 !Z8F@M,C R,3 S,3E?9&5F+GAM;-U;;6_;-A#^/F#_@7._ M;,!D67;3-D:\PLO+8*QY0>QNP[X$M$3;Q"C2(*G8[J_?4183O\B.Y(1MHT^2 M*-[Q>8[D\70'G7R@B!HU(-5,4FPT8. 3IN-QKMY@?4 MO43G6&DB.1K0F*R*BNE"TO%$HY_#7U J="8X)XR1!;J@'/.08H;Z%O&OJ,?# M.NHRAFZ-F *8BLA[$M4SK8SR_X8&-YB*JT[-D,^XSX>2U84< [A&R[<=:\N> M;?-LY;M&_C_7'[JAQ,28P^,K8'#H]36*)E<<'Q\[*=O'[K"\)%^ MZ+N*YLA?OH2NBK95.M0G$::34( "VMG#/'FVFV>:O*#IM8+Z7$4UL"Y")UB& M4C!R2T8HA=O6BRGIU!2-I\S03-LFDHQV K'HC?XCH_D-9JR&,L6?;WO;G"G7 M?D1C/^OCIP*^.T P%N%F&W@1&>&$Z7+P5,A EHU_;:Y=$YUU0O>GPD9)PZ@W4+?!E./*LL97H+>N[* MZ%FW[BHE6.B44]/W$SRN=2=S37A$(JO$H'=(.05E83$1[C